NCT00287235View on ClinicalTrials.gov

Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 30, 2000

Primary Completion Date

November 30, 2003

Study Completion Date

April 30, 2004

Conditions
Hepatic EncephalopathyLiver FailureHepatitis, ChronicLiver Cirrhosis
Interventions
DEVICE

MARS

DRUG

Standard Medical Therapy

Trial Locations (8)

10032

Columbia-Presbyterian Medical Center, New York

22908

University of Virginia, Charlottesville

35294

University of Alabama, Birmingham

48109

University of Michigan, Ann Arbor

60611

Northwestern University, Chicago

92103-8707

University of California, San Diego, San Diego

Unknown

UZ Gasthuisberg, Leuven

University Hospital of Copenhagen, Rigshospitalet, Copenhagen

All Listed Sponsors
collaborator

Gambro Renal Products, Inc.

INDUSTRY

collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

Vantive Health LLC

INDUSTRY

NCT00287235 - Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS) | Biotech Hunter | Biotech Hunter